Adrenocortical Carcinoma Clinical Trial
Official title:
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%. For patients with advanced ACC, mitotane alone or combined with traditional chemotherapy was the first-line standard treatment, but its progression-free survival was only about 1 year. However, for patients who fail the first-line treatment, there is a lack of effective treatment. For ACC patients who had failed first-line chemotherapy, a phase II clinical trial found that the objective response rate and the disease control rate of PD-1 inhibitor Keytruda were 14% and 64% respectively, and no grade 3 or 4 adverse events were observed. Anti-tumor angiogenic drugs combined with PD-1 inhibitors have shown impressive clinical data in many solid tumors. This study is aimed to evaluate the efficacy and safety of PD-1 inhibitor camrelizumab combined with apatinib in patients with recurrent or metastatic ACC after standard treatment failure, and to seek new treatment for this population.
Status | Recruiting |
Enrollment | 21 |
Est. completion date | April 1, 2025 |
Est. primary completion date | April 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histologically confirmed diagnosis of adrenocortical carcinoma; 2. Patients with metastatic or inoperable adrenocortical carcinoma that has progressed, metastasized, or recurred after first-line standard treatment (mitotane monotherapy, chemotherapy alone, mitotane combined chemotherapy); 3. Aged >=18 years; 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 5. At least one measurable lesion, according to RECIST 1.1; 6. Major organ functions within 28 days prior to treatment meet the following criteria(14 days without transfusion): HB=80g/L, ANC=1.5x10^9/L, PLT =80x10^9/L; TBIL=1.5 ULN, ALT and AST =2.5 ULN, if there exists hepatic metastases, ALT and AST =5 ULN, Cr =1.5 ULN or CCr =60ml/min; INR or PT =1.5 ULN, APTT =1.5 ULN (if the patient is receiving anticoagulant therapy, PT and APTT should be within the expected treatment range); Cardiac Markers and BNP=ULN;TSH=ULN (If TSH is abnormal, T3 and T4 should be normal) 7. Appropriate contraception should be used from the start of treatment to 120 days after the end of treatment; 8. Have signed consent form. Exclusion Criteria: 1. Patients with another primary malignancy within 5 years prior to starting the study drug, except for cured in situ cervical carcinoma and cured non-melanoma skin cancer; 2. Have central nervous system metastasis with symptoms and need hormonal intervention; 3. Had received strong CYP3A4 inhibitors within one week prior to enrollment or received strong CYP3A4 inducers within two weeks prior to enrollment; 4. Poor control of high blood pressure (SBP>140mmHg or DBP>90mmHg); 5. Congestive heart failure of New York Heart Association (NYHA) Class III or IV; 6. Thromboembolic events occurred within 1 year prior to enrollment; 7. ECG QT interval >500ms; 8. Previous systemic immunosuppressive therapy; 9. Previous anti-PD-1, anti-PD-L1 antibody or anti- CTLA-4 antibody treatment; 10. Received TKI treatment within 2 weeks prior to starting the study drug; 11. Participate in clinical trials of other interventional drugs within 4 weeks prior to starting the study drug; 12. Received systemic therapy with corticosteroids or other immunosuppressants within 2 weeks prior to starting the study drug; 13. An anti-tumor vaccine or a live vaccine was given within 4 weeks prior to starting the study drug; 14. Major surgery or severe trauma within 4 weeks prior to starting the study drug; 15. Severe infections occurred within 4 weeks prior to starting the study drug; 16. Have an active autoimmune disease or a history of autoimmune diseases; 17. Have a history of immunodeficiency; 18. Have an active tuberculosis infection; 19. Have active hepatitis; 20. Patients with symptoms of gastrointestinal bleeding or risk of bleeding; 21. Active infection, or patients are pregnant or breast-feeding. |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital, Sichuan University | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
West China Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | objective response rate | The rate of complete response and partial response. | up to 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04373265 -
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
|
Phase 1 | |
Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
Recruiting |
NCT06066333 -
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
|
Phase 2 | |
Recruiting |
NCT03127774 -
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
|
Phase 2 | |
Completed |
NCT01048892 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
|
Phase 1 | |
Recruiting |
NCT00457587 -
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
|
||
Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
Recruiting |
NCT05999292 -
Phase 1 Study of 68Ga-R8760
|
Phase 1 | |
Completed |
NCT05361083 -
First-in-human Evaluation of [18F]CETO
|
Early Phase 1 | |
Recruiting |
NCT05660889 -
Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
|
||
Completed |
NCT00003038 -
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|
||
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Enrolling by invitation |
NCT05036434 -
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
|
Phase 2 | |
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06333314 -
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
|
Phase 2 | |
Withdrawn |
NCT00469469 -
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
|
Phase 2 | |
Completed |
NCT00002608 -
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05839886 -
The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
|
||
Recruiting |
NCT05634577 -
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
|
Phase 2 |